Clinical Trial Update: A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating BRG01 in subjects with EBV-positive nasopharyngeal carcinoma has completed its Phase 1 portion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• BRG01

Snippet

Sponsor: BioSyngen Pte Ltd | Conditions: EBV-positive Nasopharyngeal Carcinoma | Phase 1 | Status: COMPLETED